Quick Answer
Inhibitor Therapeutics, Inc. reported Operating Income Loss of -$3.43 million for the year ending 2025.
- Inhibitor Therapeutics, Inc. showed an increase of +6.3% in Operating Income Loss from 2024 to 2025.
- This data is from Inhibitor Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), Inhibitor Therapeutics, Inc.'s Operating Income Loss has declined by 511.2%.
- Historical annual values: Fiscal year 2025: -$3.43 million | Fiscal year 2024: -$3.66 million | Fiscal year 2023: -$3.40 million | Fiscal year 2022: -$657.9 thousand | Fiscal year 2021: -$325.4 thousand | Fiscal year 2020: -$1.06 million | Fiscal year 2019: -$2.75 million | Fiscal year 2018: -$4.56 million | Fiscal year 2017: -$5.12 million | Fiscal year 2016: -$7.02 million | Fiscal year 2015: -$3.95 million | Fiscal year 2014: -$3.94 million | Fiscal year 2013: -$2.00 million | Fiscal year 2012: -$560.7 thousand.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: